ZBTB18

Across TCGA pan-cancer cohorts, ZBTB18 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBTB18 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZBTB18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB18 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

OV, SKCM, and UCEC are the cancer types where ZBTB18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	IV	0.028	0.759	.002	12	view →
SKCM	OS	Median	All	0.245	0.781	.008	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZBTB18–OV (OS)

Open the OV breakdown →